Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AbbVie vows to keep...

    AbbVie vows to keep drug price increases below 10 percent

    Written by supriya Published On 2017-01-12T11:20:09+05:30  |  Updated On 12 Jan 2017 11:20 AM IST
    AbbVie vows to keep drug price increases below 10 percent

    AbbVie Inc Chief Executive Richard Gonzalez promised to keep all drug price increases in 2017 under 10 percent, becoming the third global drug maker to publicly make that pledge.


    Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Gonzalez said his company would raise prices just once this year, and the percentage increases would not exceed single digits.


    AbbVie, whose rheumatoid arthritis treatment Humira is the world's biggest-selling drug, joins Allergan and Danish diabetes company Novo Nordisk as the first major drugmakers promising such a limit on price increases.


    "There's a strong debate going on right now about pricing," Gonzalez told investors. "We need to make sure we are operating in an appropriate way and demonstrating the value of the products that we have."


    Drugmakers have come under intense criticism for setting extremely high U.S. prices for new medicines, and for their practice of regularly increasing those prices, often twice a year and by double-digits.


    While Gonzalez was making his presentation the pricing debate heated up considerably, as U.S. President-elect Donald Trump attacked the pharmaceutical industry during a news conference.


    Trump said drugmakers were "getting away with murder" and promised to start a bidding process over drug pricing that would save the country billions of dollars.


    It appeared to be a renewal of a campaign promise Trump made to allow the massive U.S. Medicare health insurance program for the elderly to negotiate drug pricing, something it is currently prohibited by law from doing. Trump's comments sent shares of pharmaceutical and biotech companies lower.


    Shares of AbbVie were down 4.0 percent at $60.91 in afternoon trading.


    Prior to Trump's news conference, several top pharmaceutical executives at the JP Morgan conference expressed optimism over a Trump administration they see as likely to lower corporate tax rates and allow repatriation of cash held overseas without incurring major penalties.


    "I've never been more hopeful than I am now," Gonzalez said, while apparently unaware of Trump's comments at the time.


    Even with only single-digit price increases, Gonzalez said he expects global sales of Humira to exceed $18 billion by 2020. Humira had sales in 2015 of about $14 billion.


    Gonzalez said there remains room for considerable growth in rheumatoid arthritis and even more in psoriasis.


    "The dermatology space has lot of opportunity to continue to drive long-term growth," he said. "It's a very attractive market longer term."

    AbbVieAllerganDonald Trumpdrug priceHumiraJP Morgan Healthcare ConferenceNovo Nordiskrheumatoid arthritisRichard Gonzalez
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya
    supriya
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok